Abstracts tagged "physical function"

Abstract Number: 0235 • ACR Convergence 2021
Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?
Imke Redeker¹, Stefan Moustakis², Styliani Tsiami², Xenofon Baraliakos², Ioana Andreica², Bjoern Buehring², Juergen Braun² and Uta Kiltz², ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…
Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Uta Kiltz¹, Kirsten Hoeper², Ludwig Hammel³, Sebastian Lieb⁴, Andreas Haehle⁴ and Dirk Meyer-Olson⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, ³Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵m&i Fachklinik Bad Pyrmont, Hannover, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
Abstract Number: 0376 • ACR Convergence 2021
Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
Imke Redeker¹, Robert Landewé², Désirée van der Heijde³, Sofia Ramiro⁴, Annelies Boonen⁵, Maxime Dougados⁶, Juergen Braun⁷ and Uta Kiltz⁷, ¹German Rheumatism Research Centre (DRFZ), Berlin, Germany, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic…
Abstract Number: 0735 • ACR Convergence 2021
Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: Improved ability to walk is a key driver for people with knee osteoarthritis (OA) to seek total knee arthroplasty (TKA). However, the extent to…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 1124 • ACR Convergence 2021
Examining the Relationships Between Treatment and Pain and Physical Function Outcomes in Patients with Osteoarthritis: A Mediation Modeling Approach
Lucy Abraham¹, Robert Dworkin², Dennis C. Turk³, John D. Markman², David A. Williams⁴, Andrew G Bushmakin⁵, Jerry A. Hall⁶, David C. Semel⁷, Joseph C Cappelleri⁵ and Ruoyong Yang⁸, ¹Pfizer Ltd., Tadworth, United Kingdom, ²University of Rochester, Rochester, NY, ³University of Washington, Seattle, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, New York, NY, ⁸Pfizer Inc., New York, NY
Background/Purpose: To better understand the complex relationships between treatment and pain and physical function (PF) outcomes, we investigated a set of mediation models of osteoarthritis…
Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1647 • ACR Convergence 2020
An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain
Marie-Noelle Horcajada¹, Maurice Beaumont², Nicolas Sauvageot², Madleen Saboundjian¹, Laure Poquet¹, Anne-Christine Hick³, Berenice Costes⁴ and Yves Henrotin⁵, ¹Nestle Research, EPFL Innovation Park, Lausanne, Switzerland, ²Nestle Research, Clinical Development Unit, Lausanne, Switzerland, ³Artialis SA, Liège, Belgium, ⁴Artialis SA, Liege, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: The aim of this study was to investigate the effects of a 6-month intervention with an Olive Leaf Extract (OLE) standardized for oleuropein content…
Abstract Number: 0140 • ACR Convergence 2020
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis
Philip G Conaghan¹, Robert Dworkin², Thomas Schnitzer³, Francis Berenbaum⁴, Andrew Bushmakin⁵, Joseph Cappelleri⁵, Lars Viktrup⁶ and Lucy Abraham⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Sorbonne Universite�, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Tadworth, United Kingdom
Background/Purpose: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a disease-specific measure of osteoarthritis (OA) symptoms (pain and stiffness) and functional impairment regularly…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…
Abstract Number: 0322 • ACR Convergence 2020
Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis
Dan Webster¹, Rebecca Haberman², Lourdes Perez-Chada³, Stockard Simon⁴, Woody MacDuffie⁴, Michael DePhillips⁵, Soumya Reddy⁶, Alexis Ogdie⁷, Lara Mangravite⁴, Joseph Merola⁸ and Jose Scher², ¹Sage Bionetworks, Seattle, WA, ²NYU School of Medicine, New York City, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Sage Bionetworks, Seattle, ⁵SDP Digital, Seattle, ⁶NYU School of Medicine, New York, NY, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: The COVID-19 pandemic has increasingly driven clinical care into remote settings, where patients with immune-mediated and inflammatory diseases struggle to convey symptom severity to…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…

« Previous Page
1
…
3
4
5
6
7
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].